Adjusts deep brain stimulation settings to reduce speech problems in Parkinson's
Tests changing brain stimulation strength in adults with Parkinson's and speech difficulty.
Plain-language title generated from the registry record
Registry title: REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis
Key facts
- Where
- Bern, SwitzerlandSee the site
Where in Switzerland
- University Hospital Inselspital, BerneBern, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT05182892
- Record updated
- 9 April 2025
- Original description
The investigators' objective is to improve L-dopa sensitive PD-related dysarthria and at the same time reduce DBS-induced speech disorders with the help of automated acoustic analysis in patients with STN-DBS-induced dysarthria.Read full original descriptionShow less
REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis
The investigators' objective is to improve L-dopa sensitive PD-related dysarthria and at the same time reduce DBS-induced speech disorders with the help of automated acoustic analysis in patients with STN-DBS-induced dysarthria.
Inclusion: Idiopathic Parkinson-Syndrome according to the Movement Disorders Society Criteria; Treatment with bilateral deep brain stimulation in the subthalamic nucleus (for parts 1, 2 and 3); Time since DBS-STN operation ≥ 3 month (for parts 1, 2 and 3); Able to give informed consent as documented by signature; Fluent in Swiss-German or German; STN-DBS-induced dysarthria. In an operational definition, all PD-patients who reported -worsening of speech time-locked to STN-DBS implantation or patients with dysarthria on chronic stimulation improving with reduction of stimulation amplitudes in the context of postoperative routine follow up will be defined as having STN-DBS-induced dysarthria.
Exclusion: Change of parkinsonian medication in the last four weeks prior to inclusion in part 1 and 3; Change of STN-DBS parameters in the last four weeks prior to inclusion (for parts 1 and 3); Dysarthria caused in addition by a condition other than PD or DBS (e.g. stroke, myasthenia); Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders and dementia. A Montreal Cognitive Assesment (MoCa) will be performed and patients with ≤ 20 of 30 points will be excluded; Clinical diagnosis of aphasia; Depression with acute suicidal ideation; Pregnant women.